DOCSLIB.ORG

Veterinary Formulary List Listed As Generic (Brand) Abelcet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Veterinary Formulary List Listed As Generic (Brand) Abelcet Veterinary Formulary List Listed as Generic (Brand) Amiloride (Midamor) A Aminocaproic Acid (Amicar) Abelcet Aminopentamide (Centrine) Acepromazine (ACP, Promace) Aminophylline (Norphyl, Phyllocontin) Acetaminophen (Tylenol) Amiodarone (Cordarone) Acetazolamide (Diamox) Amitraz (Mitaban) Acetylcysteine (Acetadote) Amitriptyline (Elavil) Aciclovir (Zovirax) Amlodipine (Norvasc) ACP Ammonium Chloride (Uroeze) ACTH Amoxicillin (Amoxil, Moxatag, Trimox) Actidose Aqua Amoxicillin/Clavulanate (Augmentin, Clavamox) Actinomycin - D (Dactinomycin) Amphotericin (Abelcet, Ambisome, Fungizone) Activated Charcoal (Actidose Aqua, Liqui-Char, UAA Gel, Ampicillin (Principen, Polyflex) Toxiban) Ancotil Actrapid Antepsin Acular Antirobe Adequan Antisedan Afrazine Antivenom AK-NaCl Antivert Aknemin Antizol Albon Apixaban (Eliquis) Albuterol (Salbutamol, Proventil, Ventolin) Apomorphine (Apokyn) Aldactone Apoquel Alendronate (Fosamax) Apraclonidine (Iopidine) Alfaxalone (Alfaxan) Apresoline Alfaxan Ara-C (Cytostar-U) Alfentanil (Alfenta) Aranesp Alkeran Arava Allercept Aredia Allerpaws Argipressin Allopurinol (Zyloprim, Aloprim) Artificial Tears (Lacri-Lube, Lubri-Tears) Alprazolam (Xanax) Asparaginase (Elspar) Alprostadil (Prostin) Aspirin Alteplase (Activase, Cathflo) Atenolol (Tenormin) Alucap Atipamezole (Antisedan) Aluminum Acetate (Domeboro, Burow’s Solution) Ativan Aluminum Hydroxide (Alucap) Atopica Aluminum Magnesium (Gaviscon, Maalox) Atovaquone (Mepron) Amantadine (Symmetrel) Atracurium (Tracrium) Ambisome Atropine Amforol Augmentin Amicar Aurizon Amikacin (Amikin) Auroto Amikin Axid Azarga Calcijex Azathioprine (Imuran) Calcitriol (Calcijex, Rocaltrol) Azithromycin (Zithromax) Calcium Azodyl Calcium Carbonate (Tums) Azopt Calcium EDTA AZT Camcolit Canaural B Canesten Betamethasone / Clotrimazole (Lotrimin, Lotriderm) Canine Atopic Dermatitis Immunotherapeutic (CADI, Bactrim Canine IL-31 Bactrim DS Canine IL-31) Bactrim DS, Septra DS) Caninsulin Bactroban Capromorelin Oral Solution (Entyce) Belimumab Carafate Banamine Carboplatin (Paraplatin) Benazepril (Lotensin) Carboxamide Benlysta (Belimumab) Carprieve Benzonatate (Tessalon, Zonatuss) Carprodyl Benzoyl Peroxide (PanOxyl, Benprox, Relovox) Carprofen (Rimadyl, Carprodyl, Carprieve, Norocarp, Novox) Besifloxacin Ophthalmic (Besivance) Cartrophen Besivance Carvedilol (Coreg) Betamethasone (Diprolene, Celestone, Luxiq, Norbet) Catapres Betaxolol (Betoptic, Kerlone) Cefa-Caps Bethanechol (Urecholine) Cefa-Drops Betoptic Cefadroxil (Cefa-Tabs, Cefa-Caps, Cefa-Drops, Duricef) Bimectin Cefa-Tabs Bisacodyl (Dulcolax, Biscolax, Fleet) Cefazolin Bismuth Salts (Bismatrol, Pepto-Bisamol, Kaopectate, Kao-Tin, Cefotaxime (Claforan) Gastro-Cote) Cefovecin (Convenia) Bonefos Cefoxitin (Mefoxin) Brevibloc Cefpodoxime Proxetil (Simplicef) Bricanyl Cefprozil Brimodinine (Mirvaso, Alphagan P) Ceftazidime (Tazicef, Fortaz) Brinzolamide (Azopt) Ceftiofur (Naxcel) Bromhexine (Bromhexin, Bromex, Mucolyte) Cefuroxime (Zinacef, Ceftin) Bromfenac Opthalmic Solution (Xibrom) Cefzil (Cefprozil) Buccastem Celexa Budesonide (Entocort, Pulmicort) CellCept Bupivacaine (Marcaine, Sensorcaine) Centrine Buprenorphine (Buprenex) Cephalexin (Keflex, Rilexine) Burow’s Solution Cerenia Buscopan Cetirizine (Zyrtec) Buserelin (Suprefact) Chlorambucil (Leukeran) Buspar Chloramphenicol (Chloromycetin) Buspirone (Buspar) Chloromycetin Busulfan (Myleran) Chlorpheniramine (Chlor-Tabs, Aller-Chlor) Butorphanol (Stadol, Dolorex) Chlortetracycline (Aureomycin) Butylscopolamine (Buscopan) Cholestyramine (Questran, Prevalite) C Chondroprotec Chorionic Gonadotrophin (Chorulon) CADI Chorulon Cabergoline (Dostinex) Cidofovir (Vistide) Ciloxan D Cimetidine (Tagamet) Dacarbazine (DTIC) Cinchophen (Quinophan, Phenaquin, PLT) Dactinomycin Ciprofloxacin (Ciloxan, Cipro, Cetraxal) Dalteparin (Fragmin) Cisapride (Propulsid) Danazol (Danocrine) Cisatracurium (Nimbex) Dantrium Cisplatin Dantrolene (Dantrium) Citalopram (Celexa) Dapsone (Aczone) Clarithromycin (Biaxin) Daraprim Clavamox Darbepoetin (Aranesp) Clemastine (Tavist) DDAVP Clexane Deca Durabolin Clinacin Deferoxamine (Desferal) Clindamycin (Antirobe, Clinacin) Delmadinone Acetate (Tardak) Clodronate (Bonefos, Loron) Demadex Clofazimine (Lamprene) Demecarium Bromide (Humorsol) Clomicalm Demerol Clomipramine (Clomicalm) Denamarin (Marin) Clonazepam (Klonopin) Denosyl Clonidine (Catapres, Duraclon) Depo-Medrol Clopidogrel (Plavix) Deracoxib (Deramaxx) Clorazepate (Tranxene) Deramaxx Clotrimazole (Canesten, Lotrimin, Mycelex) Desferal Cloxacillin (Cloxapen, Tegopen) Desmopressin (DDAVP, Stimate) Co-amilozide Desoximetasone Cobalamin (Vitamin B-12) Desoxycorticosterone Pivalate (Percorten-V) Codeine Dexamethasone (Decadron, Maxidex) Colchicine (Colcrys) Dexamethasone/Neomycin/Polymyxin b (Maxitrol) Convenia Dexdomitor Cordarone Dexmedetomidine (Dexdomitor, Sileo) Cordilox Dexpanthenol (Vitamin B5) Cortavance Dextromethorphan (Delsym) Cortrosyn Dextrose Cosopt Diamox Cosyntropin (Cortrosyn) Diathal Cozaar Diazapam (Valium) Creon Diazoxide (Proglycem, Hyperstat) Cromolyn Sodium Opthalmic Solution Dibenzyline Cyclobenzaprine (Flexeril) Dichlorphenamide (Daranide) Cyclopentolate (Ak-Pentolate, Cyclogyl) Diclofenac (Voltaren) Cyclophosphamide (Cytoxan, Neosar) Dicural Cyclosporine (Atopica, Neoral, Sandimmune) Diethylstilbestrol (DES) Cyproheptadine (Periactin) Difloxacin (Dicural) Cytarabine (Depocyt, Cytosar-U, Ara-C) Diflucan Cytosar-U Difluprednate (Durezol) Cytosine Arabinoside (Depocyt, Cytosar-U, Ara-C) Digoxin (Lanoxin) Cytotec Diltiazem (Cardizem, Dilt-cd) Dimercaprol Dimethylsulfoxide (DMSO) Dinoprost Tromethamine (Lutalyse) Dinoprostone (Cervidil, Prepidil) Epinephrine Dioctyl Sodium Sulfosuccinate (DSS) Epirubicin (Ellence, Pharmorubicin) Dipentum Epoetin Alfa (Epogen / Procrit) Diphenhydramine (Benadryl) Epoetin Beta (NeoRecormon) Diphenoxylate (Lomotil) Epogen Diphenylhydantoin (Dilantin, Phenytek) Erythrocin Dipyrone (Metamizole) Erythromycin (Erythrocin) DMSO Erythropoietin Dobutamine (Dobutrex) Esmolol (Brevibloc) Dobutrex Esomeprazole (Nexium) Docusate (Correctol, Colace, Dulcolax, Docusol, Norgalax, Estradiol (Estring, Vagifem, Elestrin, Evamist) Waxsol) Ethanol Docusol Etodolac (Lodine) Dolasetron (Anzemet) Dolorex F Domeboro Famciclovir (Famvir) Domitor Famotidine (Pepcid, Fluxid) Domperidone (Motilium) Famvir Dopamine (Intropin) Fansidar Dopram- V Faverin Dorzolamide (Trusopt) Felbamate (Felbatol) Dorzolamide / Timolol (Cosopt) Feldene Doxapram (Dopram- V) Felimazole Doxepin (Silenor, Zonalon, Prudoxin) Fenofibrate (Tricor,Triglide) Doxorubicin (Doxil, Adriamycin) Fentanyl (Duragesic, Fentora, Sublimaze) Doxycycline (Vibramycin) Fentanyl Fluanisone (Hypnorm) DTIC Fentora Dulcolax Filgrastim (Neupogen) Duphalyte Finasteride (Proscar, Propecia) Duragesic Firocoxib (Previcox) Duramorph Flagyl Durezol Fleet Duricef Flexeril Florinef E Floxapen Estriol (Incurin) Flucloxacillin (Floxapen) Easotic Fluconazole (Diflucan) Edrophonium (Enlon) Flucytosine (Ancobon) Efudex Fludrocortisone (Florinef) Eliquis Flumazenil (Romazicon) Elmiron Flunixin (Banamine) Elspar Fluocinolone (Synalar) EMLA Fluorometholone (Flarex, Fluor-Op, FML) Enacard Fluorouracil (Efudex) Enalapril (Enacard, Vasotec) Fluothane Enilconazole (Fungaflor, Nuzone) Fluoxetine (Prozac, Reconcile) Enoxaparin (Clexane, Lovenox) Flurbiprofen (Ocufen) Enrofloxacin (Baytril) Fluticasone (Flonase, Veramyst) Entocort Fluvoxamine (Faverin) Epakitin FML Ephedrine Fomepizole (Antizol) Fragmin Hydroxyethyl Starch (Hetastarch, Voluven) Framycetin (Soframycin) Hydroxypropyl Methylcellulose (Genteal Gel) Fungizone Hydroxyurea (Hydrea) Furadantin Hydroxyzine (Vistaril, Atarax) Furosemide (Lasix) Hyoscine (Buscopan) Hypertonic Saline G Hypnorm Gabapentin (Neurontin) Hypurin Galliprant (Grapiprant) Gammagard I Gastrocote Isoflurane (IsoFlo) Gas-X Ibaflin Gatifloxacin Opthalmic Drops Ibafloxacin (Ibaflin) Gaviscon Ichon Gemcitabine (Gemzar) Idoxuridine (Dendrid) Gemfibrozil (Lopid) Imepitoin (Pexion) Gemzar Imidazole Genotropin Imidocarb (Imizol) Gentamicin (Gentak) Imipenem Cilastatin (Primaxin) Gentamicin / Betamethasone / Clotrimazole (Otomax) Imipramine (Tofranil) Genteal Gel Imiquimod (Aldara, Zyclara) Glibenclamide (Micronase, Glynase) Imizol Glipizide (Glucotrol) Immune Globulin (Gammagard) Glucagen Imodium Glucagon (GlucaGen) Imuran Glucantime Incurin Glucose Inderal Glutamine Insulatard Glycopyrronium Bromide (Robinul) Insulin (Humulin, Lantus, ProZinc) Goodwinol Interferon (Roferon-A, Intron, Viraferon) Granisetron (Sancuso, Granisol) Intralipid Granocyte Intron Griseofulvin (Fulvicin, GrisPEG, Grisactin) Iopidine Guaifenesin (Mucinex, Robitussin) Iron Dextran (Infed, Dexferrum) IsoFlo H Isopropyl Alcohol Halothane (Fluothane) Isoproterenol (Isuprel) Haponal Isotretinoin (Accutane, Claravis, Isotrex, Roaccutane) Hemoglobin Glutamer (Oxyglobin) Isotrex Heparin Ispagel Hetastarch Ispaghula (Fybogel, Psyllium, Ispagel, Vetasyl) Hiprex Isuprel Humatrope Itraconazole (Sporanox, Itrafungol) Humorsol Itrafungol Humulin IV Fluids (Normosol, Lactated Ringers, Sodium Chloride) Hydralazine (Apresoline) Ivelip Hydrea Ivermectin (Ivomec, Bimectin) Hydrochlorothiazide (Diuril, Esidrix, Microzide) Ivomec Hydrocodone / Homatropine (Tussigon / Hycodan) Hydrocortisone (Cortavance, Cortef, Cortifoam, Locoid) Hydrocortisone / Miconazole / Gentamicin (Easotic) Lubri-Tears K Lucentis (Ranibizumab) Kanamycin (Kantrex) Lustral Kenalog Lutalyse Keppra Lyrica Ketamine (Ketaset, Vetalar-V) Lysine Ketaset Lysodren Ketoconazole (Nizoral) Ketorolac
Load more

Recommended publications
  • Pain Management E-Book
    VetEdPlus E-BOOK RESOURCES Pain Management E-Book WHAT’S INSIDE Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Grapiprant for Control of Osteoarthritis Pain in Dogs Use of Acupuncture for Pain Management Regional Anesthesia for the Dentistry and Oral Surgery Patient A SUPPLEMENT TO Laser Therapy for Treatment of Joint Disease in Dogs and Cats Manipulative Therapies for Hip and Back Hypomobility in Dogs E-BOOK PEER REVIEWED CONTINUING EDUCATION Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Tamara Grubb, DVM, PhD, DACVAA Associate Professor, Anesthesia and Analgesia Washington State University College of Veterinary Medicine Pain is not always a bad thing, and all pain is not Untreated or undertreated pain can cause myriad the same. Acute (protective) pain differs from adverse effects, including but not limited to chronic (maladaptive) pain in terms of function insomnia, anorexia, immunosuppression, and treatment. This article describes the types of cachexia, delayed wound healing, increased pain pain, the reasons why chronic pain can be sensation, hypertension, and behavior changes difficult to treat, and the use of gabapentin and that can lead to changes in the human–animal amantadine for treatment of chronic pain. bond.2 Hence, we administer analgesic drugs to patients with acute pain, not to eliminate the protective portion but to control the pain ACUTE PAIN beyond that needed for protection (i.e., the pain Acute pain in response to tissue damage is often that negatively affects normal physiologic called protective pain because it causes the processes and healing). This latter type of pain patient to withdraw tissue that is being damaged decreases quality of life without providing any to protect it from further injury (e.g., a dog adaptive protective mechanisms and is thus withdrawing a paw after it steps on something called maladaptive pain.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Pexion, Imepitoin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pexion 100 mg tablets for dogs Pexion 400 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: Imepitoin 100 mg Imepitoin 400 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets White, oblong, half-scored tablets with embedded logo “I 01” (100 mg) or “I 02” (400 mg) on one side. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 Target species Dog 4.2 Indications for use, specifying the target species For the reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs for use after careful evaluation of alternative treatment options. 4.3 Contraindications Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs with severely impaired hepatic function, severe renal or severe cardiovascular disorders (see section 4.7). 4.4 Special warnings The pharmacological response to imepitoin may vary and efficacy may not be complete. Nevertheless imepitoin is considered to be a suitable treatment option in some dogs because of its safety profile (see section 5.1). On treatment, some dogs will be free of seizures, in other dogs a reduction of the number of seizures will be observed, whilst others may be non-responders. In non-responders, an increase in seizure frequency may be observed. Should seizures not be adequately controlled, further diagnostic measures and other antiepileptic treatment should be considered. The benefit/risk assessment for the individual dog should take into account the details in the product literature.
    [Show full text]
  • T 1635/09 T 1635/09 T 1635/09 (Verfahrenssprache) (Translation) (Traduction)
    542 Amtsblatt EPA Official Journal EPO Journal officiel OEB 11/2011 Entscheidung der Technischen Decision of Technical Board Décision de la Chambre de Beschwerdekammer 3.3.02 of Appeal 3.3.02 dated recours technique 3.3.02 en date vom 27. Oktober 2010 27 October 2010 du 27 octobre 2010 T 1635/09 T 1635/09 T 1635/09 (Verfahrenssprache) (Translation) (Traduction) Zusammensetzung der Kammer: Composition of the Board: Composition de la Chambre : Vorsitzender: Chairman: Président : U. Oswald U. Oswald U. Oswald Mitglieder: Members: Membres : A. Lindner, L. Bühler A. Lindner, L. Bühler A. Lindner, L. Bühler Patentinhaber/Beschwerdeführer: Patent proprietor/Appellant: Titulaire/requérant : Bayer Schering Pharma Bayer Schering Pharma Bayer Schering Pharma Aktiengesellschaft Aktiengesellschaft Aktiengesellschaft Einsprechender 01/ Opponent 01/Appellant: Opposant 01/requérant : Beschwerdeführer: STRAGEN PHARMA SA STRAGEN PHARMA SA STRAGEN PHARMA SA Einsprechender 02/ Opponent 02/Appellant: Opposant 02/requérant : Beschwerdeführer: Laboratorios Léon Farma, S.A. Laboratorios Léon Farma, S.A. Laboratorios Léon Farma, S.A. Einsprechender 03/ Opponent 03/Appellant: Opposant 03/requérant : Beschwerdeführer: Sandoz AG Sandoz AG Sandoz AG Einsprechender 04/ Opponent 04/Party to the Opposant 04/partie à la procédure : Verfahrensbeteiligter: proceedings: Helm AG Helm AG Helm AG Stichwort: Headword: Référence : Zusammensetzung für Empfängnisver- Composition for contraception/BAYER Composition contraceptive/BAYER hütung/BAYER SCHERING PHARMA AG SCHERING PHARMA
    [Show full text]
  • Download Drug Labels List
    Syringe Labelling System Price Per Label Description/Drug Name Item No. Quanitiy Per Pack Pack Abciximab 99801 2 x 500 roll's £6.30 Abidec 100602 2 x 500 roll's £6.30 Acepromazine 99802 2 x 500 roll's £6.30 Acetazolamide 99803 2 x 500 roll's £6.30 Acetylcholine 99804 2 x 500 roll's £6.30 Acetylcysteine 99805 2 x 500 roll's £6.30 Acetylsalicylic Acid 99806 2 x 500 roll's £6.30 Aciclovir 99807 2 x 500 roll's £6.30 ACP/Buprenorphine 100208 2 x 500 roll's £6.30 Actrapid Insulin 99808 2 x 500 roll's £6.30 Adenosine 99809 2 x 500 roll's £6.30 Adrenaline (Top Half Black, Bottom Violet, Violet Text) 99810 2 x 500 roll's £6.30 Adrenaline/Epinephrine 99811 2 x 500 roll's £6.30 Albumin Solution 99812 2 x 500 roll's £6.30 Alchol 99813 2 x 500 roll's £6.30 Alemtuzmab 99814 2 x 500 roll's £6.30 ALERT 100243 2 x 500 roll's £6.30 Alfaxalone 99815 2 x 500 roll's £6.30 Alfentanil 99816 2 x 500 roll's £6.30 Alfentanil 99817 2 x 500 roll's £6.30 Alteplase 99818 2 x 500 roll's £6.30 Amikacin 99819 2 x 500 roll's £6.30 Aminophylline 99820 2 x 500 roll's £6.30 Amiodarone 100194 2 x 500 roll's £6.30 Amoxicillin 100195 2 x 500 roll's £6.30 Amphotericin 99821 2 x 500 roll's £6.30 Ampicillin 99822 2 x 500 roll's £6.30 Antibiotic 99823 2 x 500 roll's £6.30 Anticoagulant 99824 2 x 500 roll's £6.30 Antifungal 100228 2 x 500 roll's £6.30 Antiseptic 99825 2 x 500 roll's £6.30 Aprotinin 99826 2 x 500 roll's £6.30 Aqueous Iodine 99827 2 x 500 roll's £6.30 Arterial 100259 2 x 500 roll's £6.30 Arterial ( Line Label - White with Red Writing) 100176 2 x 500 roll's £6.30 Arterial
    [Show full text]
  • Cardiovascular Monitoring with Acetylcholinesterase Inhibitors: a Clinical Protocol† Jeremy P
    Advances in Psychiatric Treatment (2007), vol. 13, 178–184 doi: 10.1192/apt.bp.106.002725 Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol† Jeremy P. Rowland, John Rigby, Adam C. Harper & Rosalind Rowland Abstract There has been significant anxiety among prescribers regarding the potential for cardiac adverse effects associated with acetylcholinesterase (AChE) inhibitors in Alzheimer’s disease. There is no consensus on how to manage this cardiovascular risk, and memory clinics vary widely in their practice. Review of published evidence reveals that the incidence of cardiovascular side-effects is low, and that serious adverse events are rare. Intensive cardiovascular screening such as pre-treatment electrocardiograms or 24 h cardiac monitoring is not justified. Furthermore, there are no high-risk groups to target. This article suggests pragmatic guidelines for managing cardiovascular risk in patients receiving AChE inhibitors. The guidelines are intended to be easy to incorporate into routine clinical practice in a memory clinic. A few years ago it was estimated that almost 18 thus followed some uncertainty as to how treatment million people worldwide had dementia (Alzheimer’s should be properly managed. Society, 2004), with Alzheimer’s disease accounting Since the manufacturers’ cautions remain (see the for over half of cases (Fratiglioni, 2000). The second- relevant entries in http://emc.medicines.org.uk) and generation acetylcholinesterase (AChE) inhibitors guidance has been unforthcoming, services now vary donepezil, rivastigmine and galantamine were widely in their practice: some, for example, require introduced into clinical practice from 1997 for the electrocardiograms (ECGs) before use and during symptomatic treatment of Alzheimer’s disease, and treatment, whereas others do not.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies
    Comparative Medicine Vol 69, No 6 Copyright 2019 December 2019 by the American Association for Laboratory Animal Science Pages 520–534 Overview A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies George J DeMarco1* and Elizabeth A Nunamaker2 One of the most significant challenges facing investigators, laboratory animal veterinarians, and IACUCs, is how to bal- ance appropriate analgesic use, animal welfare, and analgesic impact on experimental results. This is particularly true for in vivo studies on immune system function and inflammatory disease. Often times the effects of analgesic drugs on a particu- lar immune function or model are incomplete or don’t exist. Further complicating the picture is evidence of the very tight integration and bidirectional functionality between the immune system and branches of the nervous system involved in nociception and pain. These relationships have advanced the concept of understanding pain as a protective neuroimmune function and recognizing pathologic pain as a neuroimmune disease. This review strives to summarize extant literature on the effects of pain and analgesia on immune system function and inflammation in the context of preclinical in vivo studies. The authors hope this work will help to guide selection of analgesics for preclinical studies of inflammatory disease and immune system function. Abbreviations and acronyms: CB,Endocannabinoid receptor; CD,Crohn disease; CFA, Complete Freund adjuvant; CGRP,Calcitonin gene-related
    [Show full text]
  • 328 United States Tariff Commission July 1970 UNITED STATES TARIFF COMMISSION
    UNITED STATES TARIFF COMMISSION Washington IMPORTS OF BENZENOID CHEMICALS AND PRODUCTS 1969 United States General Imports of Intermediates, Dyes, Medicinals, Flavor and Perfume Materials, and Other Finished Benzenoid Products Entered on 1969 Under Schedule 4, Part 1, of The Tariff Schedules of the United States TC Publication 328 United States Tariff Commission July 1970 UNITED STATES TARIFF COMMISSION Glenn W. Sutton Bruce E. Clubb Will E. Leonard, Jr. George M. Moore Kenneth R. Mason, Seoretary Address all communications to United States Tariff Commission Washington, D. C. 20436 CONTENTS (Imports under TSUS, Schedule 4, Parts 1B and 1C) Table No. pue_ 1. Benzenoid intermediates: Summary of U.S. general imports entered under Part 1B, TSUS, by competitive status, 1969 4 2. Benzenoid intermediates: U.S. general imports entered under Part 1B, TSUS, by country of origin, 1969 and 1968 3. Benzenoid intermediates: U.S. general iml - orts entered under Part 1B, TSUS, showing competitive status, 1969 4. Finished benzenoid products: Summary of U.S.general . im- ports entered under Part 1C, TSUS, by competitive status, 1969 24 5. Finished benzenoid products: U.S. general imports entered under Part 1C, TSUS, by country of origin, 1969 and 1968 25 6. Finished benzenoid products: Summary of U.S. general imports entered under Part 1C, TSUS, by major groups and competitive status, 1969 27 7. Benzenoid dyes: U.S. general imports entered under Part 1C, TSUS, by class of application, and competitive status, 1969-- 30 8. Benzenoid dyes: U.S. general imports entered under Part 1C, TSUS, by country of origin, 1969 compared with 1968 31 9.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]